FI110668B - Användning av probiotika för primärprofylax av atopiska sjukdomar - Google Patents

Användning av probiotika för primärprofylax av atopiska sjukdomar Download PDF

Info

Publication number
FI110668B
FI110668B FI20001460A FI20001460A FI110668B FI 110668 B FI110668 B FI 110668B FI 20001460 A FI20001460 A FI 20001460A FI 20001460 A FI20001460 A FI 20001460A FI 110668 B FI110668 B FI 110668B
Authority
FI
Finland
Prior art keywords
atopic
months
children
use according
probiotic
Prior art date
Application number
FI20001460A
Other languages
English (en)
Finnish (fi)
Other versions
FI20001460A0 (sv
FI20001460A (sv
Inventor
Erika Isolauri
Seppo Salminen
Original Assignee
Aboatech Ab Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8558595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI110668(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aboatech Ab Oy filed Critical Aboatech Ab Oy
Priority to FI20001460A priority Critical patent/FI110668B/sv
Publication of FI20001460A0 publication Critical patent/FI20001460A0/sv
Priority to EP09164284.3A priority patent/EP2201955B1/en
Priority to AT01951716T priority patent/ATE439138T1/de
Priority to US10/311,706 priority patent/US7112322B2/en
Priority to ES09164285T priority patent/ES2721848T3/es
Priority to PT01951716T priority patent/PT1296694E/pt
Priority to EP09164285.0A priority patent/EP2206507B1/en
Priority to PCT/FI2001/000588 priority patent/WO2001097822A1/en
Priority to DE60139554T priority patent/DE60139554D1/de
Priority to EP01951716A priority patent/EP1296694B1/en
Priority to PT91642843T priority patent/PT2201955T/pt
Priority to DE01951716T priority patent/DE01951716T1/de
Priority to ES01951716T priority patent/ES2329549T3/es
Priority to AU72572/01A priority patent/AU784921B2/en
Priority to ES09164284T priority patent/ES2754797T3/es
Publication of FI20001460A publication Critical patent/FI20001460A/sv
Publication of FI110668B publication Critical patent/FI110668B/sv
Application granted granted Critical
Priority to US11/225,204 priority patent/US7988960B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/856—Lactobacillus casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (6)

1. Användning av levande probiotiska mjölksyre- eller bifidobakterier, som har liknande probiotiska egenskaper som stammen Lactobacillus casei ssp. rhamnosus (ATCC 53103) 5 eller stammen Bifidobacterium lactis Bb-12, och vilka har som särdrag att befrämja tidig bifidogen tarmkanalmikroflora, för att framställa en sammansättning, som är användbar för primärprofylax av atopiska sjukdomar hos ett smäbarn med hög risk för atopiska sjuk-domar, för att administreras tili en gravid kvinna under ätminstone tva veckor före förlossningen, och efter förlossningen tili det nyfödda smäbarnet under ätminstone tva 10 mänader.
2. Användning enligt patentkravet 1, väri sammansättningen administreras efter förlossningen via den ammande modern.
3. Användning enligt patentkravet 1 eller 2, väri sammansättningen innehäller ca 1 x 108 - ca 1 x 1010 kolonibildande enheter av probiotiska bakterier.
4. Användning enligt nägot av patentkraven 1-3, väri mjölksyrebakterierna är av stammen Lactobacillus casei ssp. rhamnosus (ATCC 53103). ;··* 20
: 5. Användning enligt nägot av patentkraven 1-3, väri bifidobakterierna är av stammen ;:1 Bifidobacterium lactis Bb-12.
6. Användning enligt nägot av patentkraven 1-3, väri de probiotiska bakterierna innefattar 25 en blandning av mjölksyrebakterier och bifidobakterier. • · • · • · » * I · I I ·
FI20001460A 2000-06-20 2000-06-20 Användning av probiotika för primärprofylax av atopiska sjukdomar FI110668B (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FI20001460A FI110668B (sv) 2000-06-20 2000-06-20 Användning av probiotika för primärprofylax av atopiska sjukdomar
ES09164284T ES2754797T3 (es) 2000-06-20 2001-06-20 Bifidobacterium lactis Bb-12 en prevención primaria de enfermedades atópicas
PCT/FI2001/000588 WO2001097822A1 (en) 2000-06-20 2001-06-20 Probiotics in primary prevention of atopic diseases
PT91642843T PT2201955T (pt) 2000-06-20 2001-06-20 Bifidobacterium lactis bb-12 na prevenção primária de doenças atópicas
US10/311,706 US7112322B2 (en) 2000-06-20 2001-06-20 Probiotics in primary prevention of atopic diseases
ES09164285T ES2721848T3 (es) 2000-06-20 2001-06-20 Probióticos para su uso en la prevención primaria de enfermedades atópicas
PT01951716T PT1296694E (pt) 2000-06-20 2001-06-20 Probióticos na prevenção primária de doenças atópicas
EP09164285.0A EP2206507B1 (en) 2000-06-20 2001-06-20 Probiotics for use in primary prevention of atopic diseases
EP09164284.3A EP2201955B1 (en) 2000-06-20 2001-06-20 Bifidobacterium lactis Bb-12 in primary prevention of atopic diseases
DE60139554T DE60139554D1 (de) 2000-06-20 2001-06-20 Probiotika zur primären prävention atopischer erkrankungen
EP01951716A EP1296694B1 (en) 2000-06-20 2001-06-20 Probiotics in primary prevention of atopic diseases
AT01951716T ATE439138T1 (de) 2000-06-20 2001-06-20 Probiotika zur primären prävention atopischer erkrankungen
DE01951716T DE01951716T1 (de) 2000-06-20 2001-06-20 Probiotika zur primären prävention atopischer erkrankungen
ES01951716T ES2329549T3 (es) 2000-06-20 2001-06-20 Probioticos para la prevencion primaria de enfermedades atopicas.
AU72572/01A AU784921B2 (en) 2000-06-20 2001-06-20 Probiotics in primary prevention of atopic diseases
US11/225,204 US7988960B2 (en) 2000-06-20 2005-09-14 Probiotics in primary prevention of atopic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20001460 2000-06-20
FI20001460A FI110668B (sv) 2000-06-20 2000-06-20 Användning av probiotika för primärprofylax av atopiska sjukdomar

Publications (3)

Publication Number Publication Date
FI20001460A0 FI20001460A0 (sv) 2000-06-20
FI20001460A FI20001460A (sv) 2001-12-21
FI110668B true FI110668B (sv) 2003-03-14

Family

ID=8558595

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20001460A FI110668B (sv) 2000-06-20 2000-06-20 Användning av probiotika för primärprofylax av atopiska sjukdomar

Country Status (9)

Country Link
US (2) US7112322B2 (sv)
EP (3) EP1296694B1 (sv)
AT (1) ATE439138T1 (sv)
AU (1) AU784921B2 (sv)
DE (2) DE01951716T1 (sv)
ES (3) ES2721848T3 (sv)
FI (1) FI110668B (sv)
PT (2) PT1296694E (sv)
WO (1) WO2001097822A1 (sv)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
JP4212838B2 (ja) 2002-06-26 2009-01-21 カルピス株式会社 抗アレルギー剤
JP4850715B2 (ja) 2003-12-17 2012-01-11 エヌ．ブイ．・ヌートリシア 乳酸産生菌及び肺機能
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
FR2876029B1 (fr) * 2004-10-04 2008-11-14 Oreal Composition cosmetique et/ou dermatologique pour peaux sensibles.
EP1642570A1 (fr) 2004-10-04 2006-04-05 L'oreal Composition cosmétique et/ou dermatologique pour peaux sensibles
EP1731137A1 (fr) * 2005-06-08 2006-12-13 Nestec S.A. Composition cosmétique ou dermatologique pour peaux sèches et/ou sensibles
AU2005291098B2 (en) * 2004-10-04 2011-11-24 L'oreal Cosmetic and/or dermatological composition for sensitive skins
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
RU2270248C1 (ru) * 2004-12-31 2006-02-20 Открытое акционерное общество "Лианозовский молочный комбинат" Штамм бифидобактерий bifidobacterium lactis 668, используемый для приготовления кисломолочных, ферментированных и неферментированных пищевых продуктов, биологически активных добавок, бактериальных препаратов и косметических средств
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
BRPI0609093B1 (pt) 2005-05-11 2018-12-18 Chr Hansen As processo para preparar uma cepa de bifidobacterium sp. que contém um gene tetw mutante em seu cromossomo, cepa de bifidobacterium e uso da mesma
JP2009067679A (ja) * 2005-12-27 2009-04-02 Univ Of Tokushima 抗ヒスタミン作用を有する医薬
NZ571158A (en) 2006-03-10 2011-08-26 Nutricia Nv Use of non-digestible saccharides administered to a pregnant woman for giving an infant the best start after birth
US8226936B2 (en) 2006-11-15 2012-07-24 Chr-Hansen A/S Tetracycline-sensitive bifidobacteria strains
US20100092429A1 (en) 2006-12-11 2010-04-15 Danisco A/S Composition
KR20100014523A (ko) * 2007-02-22 2010-02-10 위르겐 슈레첸메이르 인간의 알레르기 반응을 예방, 억제 또는 제거하는 프로바이오틱 그램-양성 박테리아
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
CN101273737B (zh) * 2007-03-28 2011-08-24 哈尔滨正方科技有限公司 一种在常温下保持高活菌数的发酵乳饮料的制备方法
EP1974734A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
EP2145310A4 (en) * 2007-04-30 2013-04-24 Clinical Decision Support Llc SYSTEM AND METHOD FOR COMPUTERIZED DIAGNOSTIC ARBITRATOR AND MEDICAL ADVICE
FR2920305B1 (fr) 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
FR2920304B1 (fr) 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
ES2550499T3 (es) 2008-03-28 2015-11-10 Nestec S.A. Probióticos de uso en mamíferos hembra gestantes para aumentar la inmunidad de sus crías
US20110053889A1 (en) * 2008-09-02 2011-03-03 Joanne Szabo Prenatal and postnatal screening and treatment of critical monosaccharide deficiencies for neurologic and immunologic function
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
JP2013507394A (ja) * 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
CN102269858A (zh) 2010-06-02 2011-12-07 北京智朗芯光科技有限公司 自动聚焦系统和自动聚焦方法
SG186449A1 (en) * 2010-06-30 2013-01-30 Nestec Sa Use of caftaric acid and lactic bacterium in food supplement for regulating skin pigmentation
CA2822497C (en) 2010-12-31 2020-07-28 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
NZ611807A (en) 2010-12-31 2015-02-27 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
EE05750B1 (et) 2011-02-25 2015-06-15 OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tüvi Lactobacillus gasseri MCC2 DSM 23882 ning selle kasutamine
EP2510932A1 (en) 2011-04-15 2012-10-17 Nestec S.A. Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny
MX352677B (es) 2011-06-20 2017-12-04 Heinz Co Brands H J Llc Composiciones probioticas y metodos.
DK2734210T3 (en) 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
BR112014004772A2 (pt) 2011-08-29 2017-03-21 Abbott Lab oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal
EP2617296A1 (en) * 2012-01-19 2013-07-24 Nestec S.A. A composition comprising specific Lactobacillus helveticus strains and reducing food and/or respiratory allergy symptoms
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
DK3351554T3 (da) 2012-06-18 2021-08-30 Heinz Co Brands H J Llc Glutenrelaterede forstyrrelser
WO2014052438A1 (en) 2012-09-25 2014-04-03 Regents Of The University Of Minnesota Methods for making and using antimicrobial peptides
PT2994150T (pt) 2013-05-10 2019-06-14 Heinz Co Brands H J Llc Probióticos e métodos de utilização
US20150064304A1 (en) * 2013-09-03 2015-03-05 Mario Medri Probiotic lozenge, method of making same, and uses thereof
AU2014350419B2 (en) * 2013-11-15 2019-10-24 Société des Produits Nestlé S.A. Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section
WO2015090349A1 (en) 2013-12-16 2015-06-25 Nestec S.A. Probiotic nutritional intervention during pregnancy and optionally lactation to reduce risk of allergy in infants
EP2886660A1 (en) * 2013-12-20 2015-06-24 Rigas Tehniska universitate A fluorescent in situ hybridization method for identification of a microorganism
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3270938A4 (en) * 2015-03-18 2018-12-19 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
CA2950839C (en) * 2016-01-30 2023-09-12 Cooper Technologies Company Equipment rack and components thereof
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
JP7407195B2 (ja) * 2018-12-21 2023-12-28 ソシエテ・デ・プロデュイ・ネスレ・エス・アー アレルギー性疾患の治療のためのプロバイオティクスの組み合わせ
WO2021138599A1 (en) * 2020-01-03 2021-07-08 Forte Subsidiary, Inc. Cosmetic compositions
CA3202748A1 (en) * 2020-11-24 2022-06-02 Johnson & Johnson Consumer Inc. Methods of preventing, delaying or ameliorating atopic diseases
WO2024042229A1 (en) 2022-08-25 2024-02-29 Chr. Hansen A/S Bifidobacterium strains with improved stability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591446A (en) * 1989-04-04 1997-01-07 Beiersdorf, A.G. Methods and agents for the prophylaxis of atopy
US5246591A (en) * 1990-07-13 1993-09-21 Pact, Incorporated Separation of metal ions on an anion exchange resin by chromatographic elution
BE1009359A7 (fr) 1995-05-19 1997-02-04 Univ Bruxelles Procede de detection et/ou de quantification de ligands specifiques d'une pathologie liee a une reponse allergique.
FI104465B (sv) * 1995-06-14 2000-02-15 Valio Oy Proteinhydrolysat för behandling och förebyggande av allergier samt framställning och användning av dessa
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
GB9808579D0 (en) 1998-04-22 1998-06-24 Novartis Nutrition Ag Improvements in or relating to organic compounds
JP4010062B2 (ja) * 1998-09-02 2007-11-21 医療法人社団青藍会 アトピー性皮膚炎を防ぐ保健食品
JP2000086524A (ja) * 1998-09-05 2000-03-28 Shadan Seirankai 生きた腸内細菌を含有する抗アレルギー剤
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases

Also Published As

Publication number Publication date
AU7257201A (en) 2002-01-02
DE01951716T1 (de) 2005-06-23
FI20001460A0 (sv) 2000-06-20
WO2001097822A1 (en) 2001-12-27
ES2754797T3 (es) 2020-04-20
PT1296694E (pt) 2009-10-28
US7988960B2 (en) 2011-08-02
ES2329549T3 (es) 2009-11-27
EP2206507B1 (en) 2019-03-13
US20060013806A1 (en) 2006-01-19
US20030180272A1 (en) 2003-09-25
EP2201955A1 (en) 2010-06-30
PT2201955T (pt) 2019-11-25
AU784921B2 (en) 2006-07-27
EP2201955B1 (en) 2019-08-14
EP1296694B1 (en) 2009-08-12
DE60139554D1 (de) 2009-09-24
EP2206507A1 (en) 2010-07-14
EP1296694A1 (en) 2003-04-02
US7112322B2 (en) 2006-09-26
FI20001460A (sv) 2001-12-21
ES2721848T3 (es) 2019-08-05
ATE439138T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
FI110668B (sv) Användning av probiotika för primärprofylax av atopiska sjukdomar
Adak et al. An insight into gut microbiota and its functionalities
Dzidic et al. Oral microbiota maturation during the first 7 years of life in relation to allergy development
JP5117171B2 (ja) 抗アレルギーの乳酸菌
Pedrosa et al. Survival of yogurt-containing organisms and Lactobacillus gasseri (ADH) and their effect on bacterial enzyme activity in the gastrointestinal tract of healthy and hypochlorhydric elderly subjects
Kalliomäki et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing
Duffy et al. Modulation of rotavirus enteritis during breast-feeding: implications on alterations in the intestinal bacterial flora
US9707258B2 (en) Bioconversion of milk with Bifidobacterium breve for treatment of allergic manifestions in infants
BG107299A (bg) Употреба на lactobacillus casei в имуностимулиращи пептиди
JP6985342B2 (ja) ビフィドバクテリウム ラクティス ｇｋｋ２、それを含む組成物、およびアレルギー性喘息改善のためのその使用
JP2020523329A (ja) バチルス・コアグランスの脂質低下効果
JP2023037613A (ja) 乳酸菌含有組成物
US11723936B2 (en) Therapeutic uses of Lactobacillus plantarum
CN101503662B (zh) 用于抗过敏症状的微生物株、其组合物和以此微生物株刺激细胞产生干扰素-γ的方法
Yamashita et al. Intake safety of Lactobacillus helveticus SBT2171 and its effects on nasal and ocular symptoms associated with mites and house dust: An open-label study and a randomized, double-blind, placebo-controlled, parallel group study
CN111617061A (zh) 一种亚精胺在制备提高毛螺菌属细菌丰度制剂中的应用
Mosaddek et al. Effect of probiotics in the treatment of acute watery diarrhoea in children admitted to a tertiary care hospital in Bangladesh: a non-randomized prospective clinical trial
WO2021059241A1 (en) Microbiome compositions and methods of treatment of atopic diseases
Özdemir et al. [Retracted] Preventative and Therapeutic Probiotic Use in Allergic Skin Conditions: Experimental and Clinical Findings
CN114990004B (zh) 一种分泌型免疫球蛋白a包裹态罗伊氏乳杆菌及防治妊娠糖尿病的应用
McDade et al. Fetal programming of immune function.
Mandal Study of Lactobacillus Isolates from Human Sources with regard to Their Beneficial Physiological Attributes
Mosaddek et al. Effect of Probiotics in Acute Watery Diarrhea in Children Admitted To a Bangladeshi Tertiary-Care Hospital: A Non-Randomized Prospective Clinical Trial
Elebeedy et al. The Healing Effect of Probiotics on Indomethacin Induced Gastric Ulcer in Rats
Shabaan et al. Study of Different Types of Gut Flora among Obese Egyptian Children

Legal Events

Date Code Title Description
RF Appeal filed
PC Transfer of assignment of patent

Owner name: NESTEC S.A.

Free format text: NESTEC S.A.

FCK Appeal rejected